Cerium Pharmaceuticals Synacthen, a treatment for infantile spasms, is no threat to Questcor's...
Cerium Pharmaceuticals Synacthen, a treatment for infantile spasms, is no threat to Questcor's (QCOR -7.3%) Acthar for a number of reasons, says PropThink's David Moskowitz. First, the drug is known to contain benzyl alcohol which has been implicated in infant toxicity, and FDA approval for a product containing this ingredient in infants is highly unlikely. Second, QCOR's Acthar Gel already has Orphan Drug status with an exclusivity for infantile spasms that doesn't expire until 2017. Lastly, infantile spasms represent only a small fraction of Acthar sales, so it would have minimal impact.
From other sites
at Zacks.com (Mar 24, 2015)
at Zacks.com (Mar 6, 2015)
at Nasdaq.com (Mar 3, 2015)
at Zacks.com (Feb 27, 2015)
at Nasdaq.com (Feb 12, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs